By pairing a Ciara remix with a twice-yearly dosing schedule, Gilead’s campaign aims to cut through longstanding stigma and close the gap in PrEP uptake.

A recent study of injectable pre-exposure prophylaxis found that twice-yearly injections of lenacapavir — marketed as Yeztugo by Gilead Sciences — do not have clinically significant interactions with ...

Add Yahoo as a preferred source to see more of our stories on Google. Ian L. Haddock founder of the normal anomaly I was born in Galveston County, Texas, the very place where, on June 19, 1865, ...

A recent study has found that lenacapavir, an injectable medication administered twice a year, is more effective at preventing HIV among gay, bisexual, and transgender people than a daily regimen of ...

Men who have sex with men (MSM) who are HIV-negative reported interest in an injectable pre-exposure prophylaxis (PrEP) that lasted longer than the daily pill, regardless of cost or coverage. This ...

Patients are already receiving the new PrEP injectable option lenacapavir in the Bay Area, though issues with insurance are complicating the process of getting shots. The new injectable was approved ...

Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden administration announced October 21. The news comes just weeks after it was announced ...

The Biden-Harris administration announced Monday a new requirement for insurance providers to cover injectable PrEP in their policies without a co-payment for consumers. The new rule, built on ...

HOUSTON — The fight against HIV has come a long way, and new advancements in prevention are changing the game. One of the latest breakthroughs is a long-lasting injectable form of PrEP (pre-exposure ...

Findings showed 99.9% of participants in the lenacapavir group did not acquire HIV infection. Twice-yearly lenacapavir was found to be superior to daily emtricitabine 200mg and tenofovir disoproxil ...

LOS ANGELES--(BUSINESS WIRE)--In light of the recently announced plan to put 2.5 million people on injectable pre-exposure prophylaxis (PrEP), specifically lenacapavir, by 2027, AIDS Healthcare ...

The first ever injectable drug that can prevent HIV has been approved for use in England and Wales. Subscribe to our newsletter for the latest sci-tech news updates. The drug, cabotegravir, would ...